SMEZ preparation was assessed for its ability to stimulate in vitro
expression by target cells of the skin-selective lymphocyte homing
receptor known as cutaneous lymphocyte-associated antigen (CLA) as
already established for other staphylococcal and streptococcal SAgs
(21, 49, 50). CLA is known to interact with E-selectin in
an interleukin-12 (IL-12)-dependent manner. The experimental assay
(49) was performed on 3 × 106 human PBMC
for 5 days in the presence of SMEZ preparation (10 and 100 ng/ml), SPEA
(100 ng/ml and 1 µg/ml), or RPMI 1640 medium as a control. The
antibody HECA-452 (a kind gift from A. M. Duijvestijn, Maastricht,
The Netherlands) was used to detect CLA. The antibody Ber-ACT8 (Dako),
which recognizes CD103, the
7 chain of the integrin receptor that
correlates with
4
7 expression of gut homing T cells, was used as
a control. Staining was performed by indirect immunofluorescence with
goat anti-mouse immunoglobulin G or goat anti-rat immunoglobulin M
F(ab)2-phycoerythrin. In each sample, irrelevant monoclonal
antibodies of the appropriate isotype were used as controls.
Fluorocytometer analysis was performed on a FACSCalibur (Becton
Dickinson, Heidelberg, Germany) using standard procedures with the
CellQuest computer program. The results were expressed as percentage of
antibody-reactive T cells per total T lymphocytes in a gate set on
lymphocyte-sized cells. The T-cell activation marker CD69 detected by
specific antibody and the skin-selective homing antigen CLA were
significantly expanded in the presence of both SMEZ and SPEA. In
contrast, the expression of gut homing receptor CD103 was not affected
(Table 2). The SMEZ/SPEA-dependent CLA
upregulation may possibly contribute to the pathogenesis of streptococcal SAg-induced skin inflammation as suggested in other studies of SAgs from gram-positive cocci (21).
The mitogenic activity of the SAgs tested was evaluated by a lymphocyte
proliferation assay on human PBMC as previously described (29). Half-maximal proliferation (10,000 cpm) in response
to the purified SMEZ was observed at a concentration of 100 pg/ml, in
comparison to 1.8 ng/ml for SPEA (data not shown). Accordingly, SMEZ is
18-fold more potent than SPEA in the lymphocyte proliferation assay.
A further consequence of cell stimulation with SAg is the induction of
massive cytokine release by target cells. As shown here, this is also
the case with SMEZ, investigated for the first time in this respect.
Cytokine release by PBMC challenged with SMEZ (0.1, 1, 10, and 100 ng/ml) was determined as reported earlier for SPEA and SPEC
(26-28). PBMC were also stimulated in parallel for
comparative purposes with 1 µg of SPEA per ml and 107 CFU
of heat-killed (1 h at 70°C), streptococci. The release of 18 cytokines in PBMC cultures after 72 h of incubation was tested (Table 3). Except for IL-6
(27), the cytokines were assayed by enzyme-linked
immunosorbent assay with the appropriate antibody kits as previously
described (24, 26-28, 30). Transforming growth factor
, RANTES, and MIP-1
were immunoassayed by specific kits (R&D
systems, Abington, United Kingdom). Both SMEZ and SPEA elicited the
release of substantial amounts of pro- and anti-inflammatory, chemotactic, hematopoietic, and Th1- and Th2-derived cytokines (Table
3). However, the cytokine-inducing capacity of SMEZ was ca. 10-fold
more potent (on a weight basis) than that of SPEA. Dose- and
time-dependent production of certain cytokines in response to various
concentrations of SMEZ and 1 µg of SPEA per ml was also investigated.
IL-12 was produced in significant amounts starting from 24 h, and
optimal release was about 400 pg/ml after 48 h in response to 10 ng of SMEZ. Gamma interferon (IFN-
) and IL-10 release increased
progressively up to 72 h for IFN-
and 96 h for IL-10 (Fig.
1a). Similar results were found for the
Th2-derived cytokines IL-4, IL-5, and IL-13 (Fig. 1b). Interestingly,
striking differences in cytokine-inducing capacity were found between
the SAgs tested and heat-killed streptococcal cells. The latter
elicited the production of low amounts of IL-2 and did not trigger
detectable tumor necrosis factor beta (TNF-
), IL-4, IL-5, and IL-13
release (Table 3). However, streptococcal cells were highly potent
inducers of IFN-
, TNF-
, IL-12 p40, and IL-12 p70, suggesting that
the bacteria themselves may evoke cytokine release via their cell wall
components, particularly peptidoglycan (13), and thereby could contribute with SAgs to the development of cytokine-mediated streptococcal pathological disorders.
A significant feature of the SAgs investigated here is their capacity
to induce the release of Th2-derived cytokines as already documented
(27, 28, 41). The production of these cytokines raises the
question of the possible involvement of bacterial SAgs in the
pathogenesis of diseases other than acute streptococcal and
staphylococcal diseases, particularly in certain allergic and
nonallergic diseases (14, 19, 20). The present results suggest that SMEZ is a potential pathogenicity factor of S. pyogenes that might play an important role in streptococcal diseases.
This work was supported by the Institut Pasteur de Lille, the
Centre Hospitalier Regional et Universitaire de Lille (grant 96/38/9713), and Association F. Aupetit.
| 1.
|
Abe, J. B.,
L. Kotzin,
K. Jugo,
M. E. Melish,
M. P Glode,
T. Kohsaka, and D. Y. M. Leung.
1992.
Selective expansion of T cells expressing T cell receptor variable regions V 2 and V 8 in Kawasaki disease.
Proc. Natl. Acad. Sci. USA
89:4066-4070[Abstract/Free Full Text].
|
| 2.
|
Alouf, J. E.,
H. Müller-Alouf, and W. Köhler.
1999.
Superantigenic Streptococcus pyogenes erythrogenic/pyrogenic exotoxins, p. 567-588.
In
J. E. Alouf, and J. H. Freer (ed.), The comprehensive sourcebook of bacterial protein toxins. Academic Press, London, England.
|
| 3.
|
Arcus, V. L.,
T. Proft,
J. A. Sigzell,
H. M. Baker,
J. D. Fraser, and E. N. Baker.
2000.
Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two superantigens from Streptococcus pyogenes.
J. Mol. Biol.
299:1159-1168.
|
| 4.
|
Burnette, W. H.
1981.
Western blotting: electrophoretic transfer of proteins from SDS polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.
Anal. Biochem.
112:195-203[CrossRef][Medline].
|
| 5.
|
Cavaillon, J.-M., and N. Haeffner-Cavaillon.
1986.
Polymyxin B inhibition of LPS-induced interleukin-1 secretion by human monocytes is dependent upon the LPS origin.
Mol. Immunol.
23:965-969[CrossRef][Medline].
|
| 6.
|
Cavaillon, J. M.,
H. Müller-Alouf, and J. E. Alouf.
1997.
Cytokines in streptococcal infections.
Adv. Exp. Med. Biol.
418:929-931[Medline].
|
| 7.
|
Champagne, E.,
A. Huchenq,
J. Sevin,
N. Casteran, and B. Rubin.
1993.
An alternative method for T-cell receptor repertoire analysis: clustering of human V-beta subfamilies selected in response to staphylococcal enterotoxins B and E.
Mol. Immunol.
30:877-886[CrossRef][Medline].
|
| 8.
|
Fast, D. J.,
P. M. Schlievert, and R. D. Nelson.
1989.
Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production.
Infect. Immun.
57:291-294[Abstract/Free Full Text].
|
| 9.
|
Geoffroy-Fauvet, C.,
H. Müller-Alouf,
E. Champagne,
J. M. Cavaillon, and J. E. Alouf.
1994.
Identification of a new extracellular superantigenic mitogen from group A Streptococci.
Zentbl. Bakteriol. Suppl.
24:91-92.
|
| 10.
|
Gerlach, D.,
W. Köhler,
H. Knöll,
L. Moràvek,
R. C. Weeks, and J. J. Ferretti.
1987.
Purification and characterisation of Streptococcus pyogenes erythrogenic toxin type A produced by a cloned gene in Streptococcus sanguis.
Zentbl. Bakteriol.
266:347-358.
|
| 11.
|
Hackett, S. P., and D. L. Stevens.
1992.
Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O.
J. Infect. Dis.
165:879-885[Medline].
|
| 12.
|
Hackett, S. P., and D. L. Stevens.
1993.
Superantigen associated with staphylococcal and streptococcal toxic shock syndrome are potent inducers of tumor necrosis factor- .
J. Infect. Dis.
168:232-235[Medline].
|
| 13.
|
Henderson, B.,
S. Poole, and M. Wilson.
1996.
Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis.
Microbiol. Rev.
60:316-341[Abstract/Free Full Text].
|
| 14.
|
Hofer, M. F.,
M. R. Lester,
P. M. Schlievert, and D. Y. M. Leung.
1995.
Upregulation of IgE synthesis by staphylococcal toxic shock syndrome toxin-1 in peripheral blood mononuclear cells from patients with atopic dermatitis.
Clin. Exp. Allergy
25:1218-1227[CrossRef][Medline].
|
| 15.
|
Hribalova, V.,
H. Knöll,
D. Gerlach, and W. Köhler.
1980.
Purification and characterization of erythrogenic toxins. II. In vivo biological activities of erythrogenic toxin produced by Streptococcus pyogenes strain NY-5.
Zentbl. Bakteriol.
248:314-322.
|
| 16.
|
Imanishi, K.,
K. Inada,
H. Akatsuda,
Y. Gu,
H. Igarishi, and T. Uchiyama.
1995.
Tumor necrosis factor production by human T cells stimulated with bacterial superantigens.
Int. J. Immunopharmacol.
17:841-848[CrossRef][Medline].
|
| 17.
|
Iwasaki, M.,
H. Igarashi,
Y. Hinuma, and T. Yutsudo.
1993.
Cloning, characterization and overexpression of a Streptococcus pyogenes gene encoding a new type of mitogenic factor.
FEBS Lett.
331:187-192[CrossRef][Medline].
|
| 18.
|
Kamezawa, Y.,
T. Nakahara,
S. Nakano,
Y. Abe,
J. Nozaki-Renard, and T. Isono.
1997.
Streptococcal mitogenic exotoxin Z, a novel acidic superantigenic toxin produced by a T1 strain of Streptococcus pyogenes.
Infect. Immun.
65:3828-3833[Abstract].
|
| 19.
|
König, B.,
K. Neuber, and W. König.
1995.
Responsiveness of peripheral blood mononulear cells from normal and atopic donors to microbial superantigens.
Int. Arch. Allergy Immunol.
106:124-133[Medline].
|
| 20.
|
Kotb, M.
1997.
Superantigens in human diseases.
Clin. Microbiol. Newsl.
19:145-150.
|
| 21.
|
Leung, D. Y. M.,
M. Gately,
A. Trumble,
B. Ferguson-Darnell,
P. M. Schlievert, and L. Pickler.
1995.
Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutanous lymphocyte-associated antigen via stimulation of IL-12.
J. Exp. Med.
181:747-753[Abstract/Free Full Text].
|
| 22.
|
Leung, D. Y. M.,
J. B. Travers,
R. Giorno,
D. A. Norris,
R. Skinner,
J. Aelion,
L. V. Kazemi,
M. H. Kim,
A. E. Trumble,
M. Kotb, and P. M. Schlievert.
1995.
Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis.
J. Clin. Investig.
96:2106-1212.
|
| 23.
|
Leung, D. Y. M.
1996.
Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin.
Clin. Exp. Immunol.
104(Suppl. 1):49-54.
|
| 24.
|
Marty, C.,
B. Misset,
F. Tamion,
C. Fitting,
J. Carlet, and J.-M. Cavaillon.
1994.
Circulating interleukin-8 concentrations in patients with muliple organ failure of septic and non septic origin.
Crit. Care Med.
22:673-679[Medline].
|
| 25.
|
Mollick, J. A.,
G. G. Miller,
J. M. Musser,
R. G. Cook,
D. Grossman, and R. R. Rich.
1993.
A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C.
J. Clin. Investig.
92:710-719.
|
| 26.
|
Müller-Alouf, H.,
J. E. Alouf,
D. Gerlach,
J. H. Ozegowski,
C. Fitting, and J.-M. Cavaillon.
1994.
Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci, and lipopolysaccharide.
Infect. Immun.
62:4915-4921[Abstract/Free Full Text].
|
| 27.
|
Müller-Alouf, H.,
J. E. Alouf,
D. Gerlach,
J. H. Ozegowski,
C. Fitting, and J. M. Cavaillon.
1996.
Human pro- and anti-inflammatory cytokine patterns induced by Streptococcus pyogenes erythrogenic (pyrogenic) exotoxin A and C superantigens.
Infect. Immun.
64:1450-1453[Abstract].
|
| 28.
|
Müller-Alouf, H.,
D. Gerlach,
P. Desreumaux,
C. Leportier,
J. E. Alouf, and M. Capron.
1997.
Streptococcal pyrogenic exotoxin A (SPEA) superantigen induced production of hematopoietic cytokines, IL-12 and IL-13 by human peripheral blood mononuclear cells.
Microb. Pathog.
23:265-272[CrossRef][Medline].
|
| 29.
|
Müller-Alouf, H.,
C. Geoffroy,
P. Geslin,
A. Bouvet,
A. Felten,
E. Günther,
J.-H. Ozegowski, and J. E. Alouf.
1997.
Streptococcal pyrogenic exotoxin A, exoenzymes, serotype and biotype profiles of Streptococcus pyogenes isolates from patients with toxic shock syndrome and other severe infections.
Zentbl. Bakteriol.
286:421-433.
|
| 30.
|
Muñoz, C.,
J. Carlet,
C. Fitting,
B. Misset,
J.-P. Pleriot, and J.-M. Cavaillon.
1991.
Dysregulation of in vitro cytokine production by monocytes during sepsis.
J. Clin. Investig.
88:1747-1754.
|
| 31.
|
Musser, J. M.,
A. R. Hauser,
M. H. Kim,
P. M. Schlievert,
K. Nelson, and R. K. Selander.
1991.
Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression.
Proc. Natl. Acad. Sci. USA
88:2668-2672[Abstract/Free Full Text].
|
| 32.
|
Nadal, D.,
R. P. Lauener,
C. P. Bregger,
A. Kaufhold,
B. Simma,
R. Lütticken, and A. Seger.
1993.
T cell activation and cytokine release in streptococcal toxic shock syndrome.
J. Pediatr.
122:727-729[Medline].
|
| 33.
|
Norgren, M., and A. Eriksson.
1997.
Streptococcal superantigens and their role in the pathogenesis of severe infections.
J. Toxicol. Toxin Rev.
16:1-32.
|
| 34.
|
Norrby-Teglund, A.,
D. Newton,
M. Kotb,
S. E. Holm, and M. Norgren.
1994.
Superantigenic properties of the group A streptococcal exotoxin SpeF (MF).
Infect. Immun.
62:5227-5233[Abstract/Free Full Text].
|
| 35.
|
Norrby-Teglund, A.,
R. Lustig, and M. Kotb.
1997.
Differential induction of Th1 versus Th2 cytokines by group A streptococcal toxic shock syndrome isolates.
Infect. Immun.
65:5209-5215[Abstract].
|
| 36.
|
Norrby-Teglund, A.,
K. Pauksens,
M. Norgren, and S. E. Holm.
1995.
Correlation between serum TNF alpha and IL-6 levels and severity of group A streptococcal infections.
Scand. J. Infect. Dis.
27:125[Medline].
|
| 37.
|
Papageorgiou, A. C.,
C. M. Collins,
D. M. Gutman,
J. B. Kline,
S. M. O'Brien,
H. S. Tranter, and K. R. Acharya.
1999.
Structural basis for recognition of superantigen streptococcal pyrogenic exotoxin A (SPEA1) by MHC class II molecules and T cell receptors.
EMBO J.
18:9-21[CrossRef][Medline].
|
| 38.
|
Proft, T.,
S. L. Moffatt,
C. J. Berkhahn, and J. D. Fraser.
1999.
Identification and characterization of novel superantigens from Streptococcus pyogenes.
J. Exp. Med.
189:89-102[Abstract/Free Full Text].
|
| 39.
|
Proft, T.,
S. L. Moffat,
K. D. Weller,
A. Paterson,
D. Martin, and D. Fraser.
2000.
The streptococcal superantigen SMEZ exhibits wide allelic variation, mosaic structure and significant antigenic variation.
J. Exp. Med.
191:1765-1776[Abstract/Free Full Text].
|
| 40.
|
Reichardt, W.,
H. Müller-Alouf,
J. E. Alouf, and W. Köhler.
1992.
Erythrogenic toxins A, B and C: occurrence of genes and exotoxin formation from clinical Streptococcus pyogenes strains associated with streptococcal toxic shock-like syndrome.
FEMS Microbiol. Lett.
100:313-322.
|
| 41.
|
Rink, L.,
J. Luhm,
M. Koester, and H. Kirchner.
1996.
Induction of a cytokine network by superantigens with parallel TH1 and TH2 stimulation.
J. Interferon Cytokine Res.
16:41-47[Medline].
|
| 42.
|
Sriskandan, S.,
T. J. Evans, and J. Cohen.
1996.
Bacterial superantigen-induced human lymphocyte responses are nitric oxide dependent and mediated by IL-12 and IFN .
J. Immunol.
156:2430-2435[Abstract].
|
| 43.
|
Sriskandan, S.,
D. Moyes, and J. Cohen.
1996.
Detection of bacterial superantigen and lymphotoxin- in patients with streptococcal toxic shock syndrome.
Lancet
348:1315-1316[Medline].
|
| 44.
|
Stevens, D. L.,
M. H. Tanner,
J. Winship,
R. Swarts,
K. M. Ries,
P. M. Schlievert, and E. Kaplan.
1989.
Severe group A streptococci associated with toxic shock like syndrome and scarlet fever toxin A.
N. Engl. J. Med.
321:1-7[Abstract].
|
| 45.
|
Tomai, M. A.,
P. M. Schlievert, and M. Kotb.
1992.
Distinct T-cell receptor V gene usage by human T lymphocytes stimulated with the streptococcal pyrogenic exotoxins and pep M5 protein.
Infect. Immun.
60:701-705[Abstract/Free Full Text].
|
| 46.
|
Toyosaki, T.,
T. Yoshioka,
Y. Tsuruta,
T. Yutsudo,
M. Iwasaki, and R. Suzuki.
1996.
Definition of the mitogenic factor (MF) as a novel streptococcal superantigen that is different from streptococcal pyrogenic exotoxins A, B and C.
Eur. J. Immunol.
26:2693-2701[Medline].
|
| 47.
|
Uchiyama, T.,
X.-J. Yan,
K. Imanishi, and J. Yagi.
1994.
Bacterial superantigens mechanism of T cell activation by the superantigens and their role in the pathogenesis of infectious diseases.
Microbiol. Immunol.
38:245-256[Medline].
|
| 48.
|
Watson, D. W.
1960.
Host-parasite factors in group A streptococcal infections. Pyrogenic and other effects of immunologic distinct exotoxins related to scarlet fever toxins.
J. Exp. Med.
111:255-284[Abstract].
|
| 49.
|
Zollner, T. M.,
M. E. Munk,
T. Keller,
V. Nuber,
W. H. Boenhnke,
S. H. E. Kaufmann,
A. M. Duijvestijn,
W. Sterry, and R. Kaufmann.
1996.
The superantigen exfoliative toxin induces cutaneous lymphocyte-associated antigen expression in peripheral human T lymphocytes.
Immunol. Lett.
49:111-116[CrossRef][Medline].
|
| 50.
|
Zollner, T. M.,
V. Nuber,
A. M. Duijvestijn,
W. H. Boehnke, and R. Kaufmann.
1997.
Superantigens but not mitogens are capable of inducing upregulation of E-selectin ligands on human T lymphocytes.
Exp. Dermatol.
6:161-166[CrossRef][Medline].
|